FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003991908> ?p ?o ?g. }

• W2003991908 endingPage "117" @default.
• W2003991908 startingPage "107" @default.
• W2003991908 abstract "Increased inflammation and aberrant angiogenesis underlie psoriasis. Here, we report that the inhibition of insulin receptor substrate-1 (IRS-1) expression with aganirsen resulted in a dose-dependent reduction (P < 0.0001) in IRS-1 protein in the cytoplasm, while IRS-1 protein remained quantitatively unchanged in the perinuclear environment. Aganirsen induced a dose-dependent increase in serine-phosphorylated IRS-1 in the soluble perinuclear-nuclear fraction, inducing IRS-1-14-3-3β protein association (P < 0.001), thereby impairing 14-3-3β-tristetraprolin protein complex and AU-rich mRNA's stability (P < 0.001). Accordingly, aganirsen inhibited (P < 0.001) in vitro the expression of interleukin-8 (IL-8), IL-12, IL-22, and tumor necrosis factor alpha (TNFα), four inflammatory mediators containing mRNA with AU-rich regions. To demonstrate the clinical relevance of this pathway, we tested the efficacy of aganirsen by topical application in a pilot, double-blind, randomized, dose-ranging study in 12 psoriatic human patients. After 6 weeks of treatment, least square mean differences with placebo were -38.9% (95% confidence interval, -75.8 to -2.0%) and -37.4% (-74.3 to -0.5%) at the doses of 0.86 and 1.72 mg/g, respectively. Lesion size reduction was associated with reduced expression of IRS-1 (P < 0.01), TNFα (P < 0.0001), and vascular endothelial growth factor (P < 0.01); reduced keratinocyte proliferation (P < 0.01); and the restoration (P < 0.02) of normal levels of infiltrating CD4(+) and CD3(+) lymphocytes in psoriatic skin lesions. These results suggest that aganirsen is a first-in-class of a new generation of antiangiogenic medicines combining anti-inflammatory activities. Aganirsen-induced downregulation of inflammatory mediators characterized by AU-rich mRNA likely underlies its beneficial clinical outcome in psoriasis. These results justify further large-scale clinical studies to establish the dose of aganirsen and its long-term efficacy in psoriasis." @default.
• W2003991908 created "2016-06-24" @default.
• W2003991908 creator A5019758388 @default.
• W2003991908 creator A5022292939 @default.
• W2003991908 creator A5041233269 @default.
• W2003991908 creator A5042928207 @default.
• W2003991908 creator A5047450767 @default.
• W2003991908 creator A5047713712 @default.
• W2003991908 creator A5066456106 @default.
• W2003991908 creator A5069701048 @default.
• W2003991908 creator A5086940618 @default.
• W2003991908 date "2014-02-06" @default.
• W2003991908 modified "2023-10-01" @default.
• W2003991908 title "The Antiangiogenic Insulin Receptor Substrate-1 Antisense Oligonucleotide Aganirsen Impairs AU-Rich mRNA Stability by Reducing 14-3-3<i>β–</i>Tristetraprolin Protein Complex, Reducing Inflammation and Psoriatic Lesion Size in Patients" @default.
• W2003991908 cites W1515371560 @default.
• W2003991908 cites W1607447489 @default.
• W2003991908 cites W1711897475 @default.
• W2003991908 cites W1782747004 @default.
• W2003991908 cites W1964131816 @default.
• W2003991908 cites W1965032245 @default.
• W2003991908 cites W1979058179 @default.
• W2003991908 cites W1997897024 @default.
• W2003991908 cites W2000292756 @default.
• W2003991908 cites W2000305036 @default.
• W2003991908 cites W2005029940 @default.
• W2003991908 cites W2006323394 @default.
• W2003991908 cites W2010351342 @default.
• W2003991908 cites W2024390477 @default.
• W2003991908 cites W2024412729 @default.
• W2003991908 cites W2026403783 @default.
• W2003991908 cites W2030537668 @default.
• W2003991908 cites W2032598909 @default.
• W2003991908 cites W2034825883 @default.
• W2003991908 cites W2035371785 @default.
• W2003991908 cites W2036260794 @default.
• W2003991908 cites W2045553696 @default.
• W2003991908 cites W2045714098 @default.
• W2003991908 cites W2046747088 @default.
• W2003991908 cites W2047886285 @default.
• W2003991908 cites W2061746946 @default.
• W2003991908 cites W2098775968 @default.
• W2003991908 cites W2117646004 @default.
• W2003991908 cites W2119123594 @default.
• W2003991908 cites W2123592143 @default.
• W2003991908 cites W2127834887 @default.
• W2003991908 cites W2128551077 @default.
• W2003991908 cites W2135834476 @default.
• W2003991908 cites W2148915104 @default.
• W2003991908 cites W2150732175 @default.
• W2003991908 cites W2561759163 @default.
• W2003991908 cites W4247798672 @default.
• W2003991908 doi "https://doi.org/10.1124/jpet.113.209346" @default.
• W2003991908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24504098" @default.
• W2003991908 hasPublicationYear "2014" @default.
• W2003991908 type Work @default.
• W2003991908 sameAs 2003991908 @default.
• W2003991908 citedByCount "10" @default.
• W2003991908 countsByYear W20039919082014 @default.
• W2003991908 countsByYear W20039919082015 @default.
• W2003991908 countsByYear W20039919082016 @default.
• W2003991908 countsByYear W20039919082017 @default.
• W2003991908 countsByYear W20039919082019 @default.
• W2003991908 countsByYear W20039919082022 @default.
• W2003991908 crossrefType "journal-article" @default.
• W2003991908 hasAuthorship W2003991908A5019758388 @default.
• W2003991908 hasAuthorship W2003991908A5022292939 @default.
• W2003991908 hasAuthorship W2003991908A5041233269 @default.
• W2003991908 hasAuthorship W2003991908A5042928207 @default.
• W2003991908 hasAuthorship W2003991908A5047450767 @default.
• W2003991908 hasAuthorship W2003991908A5047713712 @default.
• W2003991908 hasAuthorship W2003991908A5066456106 @default.
• W2003991908 hasAuthorship W2003991908A5069701048 @default.
• W2003991908 hasAuthorship W2003991908A5086940618 @default.
• W2003991908 hasConcept C104317684 @default.
• W2003991908 hasConcept C105580179 @default.
• W2003991908 hasConcept C126322002 @default.
• W2003991908 hasConcept C134018914 @default.
• W2003991908 hasConcept C153911025 @default.
• W2003991908 hasConcept C170493617 @default.
• W2003991908 hasConcept C17991360 @default.
• W2003991908 hasConcept C203014093 @default.
• W2003991908 hasConcept C2776914184 @default.
• W2003991908 hasConcept C2780564577 @default.
• W2003991908 hasConcept C2909367411 @default.
• W2003991908 hasConcept C41282012 @default.
• W2003991908 hasConcept C55493867 @default.
• W2003991908 hasConcept C71924100 @default.
• W2003991908 hasConcept C86803240 @default.
• W2003991908 hasConcept C98274493 @default.
• W2003991908 hasConceptScore W2003991908C104317684 @default.
• W2003991908 hasConceptScore W2003991908C105580179 @default.
• W2003991908 hasConceptScore W2003991908C126322002 @default.
• W2003991908 hasConceptScore W2003991908C134018914 @default.
• W2003991908 hasConceptScore W2003991908C153911025 @default.
• W2003991908 hasConceptScore W2003991908C170493617 @default.
• W2003991908 hasConceptScore W2003991908C17991360 @default.
• W2003991908 hasConceptScore W2003991908C203014093 @default.
• W2003991908 hasConceptScore W2003991908C2776914184 @default.

• next